Keywords: icn, revenues, benefit, rebetron, pharmaceuticals, posted, third-quarter
ICN revenues benefit from Rebetron
Article | 09 November 1999
ICN Pharmaceuticals has posted third-quarter revenues of $182 million,up 11%, but excluding the write-off of its assets in Yugoslavia (Marketletters passim) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
